These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 32859280)
41. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Des Guetz G; Lecaille C; Mariani P; Bennamoun M; Uzzan B; Nicolas P; Boisseau A; Sastre X; Cucherousset J; Lagorce C; Schischmanoff PO; Morere JF Anticancer Res; 2010 Oct; 30(10):4297-301. PubMed ID: 21036755 [TBL] [Abstract][Full Text] [Related]
42. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686 [TBL] [Abstract][Full Text] [Related]
43. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673 [TBL] [Abstract][Full Text] [Related]
44. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer. Lin LW; Lai PS; Chen YY; Chen CY Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330 [TBL] [Abstract][Full Text] [Related]
45. Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy. Gu J; Dong D; Long E; Tang S; Feng S; Li T; Wang L; Jiang X Int J Colorectal Dis; 2019 Dec; 34(12):2151-2159. PubMed ID: 31732877 [TBL] [Abstract][Full Text] [Related]
46. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy. Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767 [TBL] [Abstract][Full Text] [Related]
47. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451 [TBL] [Abstract][Full Text] [Related]
48. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118 [TBL] [Abstract][Full Text] [Related]
49. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R; Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560 [TBL] [Abstract][Full Text] [Related]
50. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314 [TBL] [Abstract][Full Text] [Related]
51. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625 [TBL] [Abstract][Full Text] [Related]
52. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy. Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539 [TBL] [Abstract][Full Text] [Related]
53. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Moreau LC; Rajan R; Thirlwell MP; Alcindor T Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831 [TBL] [Abstract][Full Text] [Related]
54. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217 [TBL] [Abstract][Full Text] [Related]
55. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY; Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862 [TBL] [Abstract][Full Text] [Related]
56. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076 [TBL] [Abstract][Full Text] [Related]
57. Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Carrato A; Gallego-Plazas J; Guillén-Ponce C Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056 [TBL] [Abstract][Full Text] [Related]
58. Optimal duration of adjuvant therapy for stage III colon cancer. Kadakia KC; Worrilow WM; Coley H; Salem ME Clin Adv Hematol Oncol; 2019 May; 17(5):289-298. PubMed ID: 31188808 [TBL] [Abstract][Full Text] [Related]
59. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157 [TBL] [Abstract][Full Text] [Related]
60. MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. Cecchin E; Perrone G; Nobili S; Polesel J; De Mattia E; Zanusso C; Petreni P; Lonardi S; Pella N; D'Andrea M; Errante D; Rizzolio F; Mazzei T; Landini I; Mini E; Toffoli G Pharmacogenomics J; 2015 Jun; 15(3):219-25. PubMed ID: 25331073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]